Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Fasching

Showing results (1-10 of 810) with videos related to

Pageof 81
Sort By:
The Lancet. Oncology|January 17, 2018
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?Peter A Fasching
Clinical Advances in Hematology & Oncology : H&O|May 13, 2024
PROTAC drugs in cancer carePeter A Fasching
Cancers|November 27, 2021
Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of ImprovementNaiba Nabieva, Peter A Fasching
Cancers|March 29, 2023
CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast CancerNaiba Nabieva, Peter A Fasching
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Breast Cancer and Genetic <i>BRCA1/2</i> Testing in Routine Clinical Practice: Why, When and For Whom?Michael P Lux, Peter A Fasching
The Lancet. Oncology|January 2, 2007
Hormones and genetics caught in the crossfire of preventive medicinePeter A Fasching, Matthias W Beckmann
Current Opinion in Obstetrics & Gynecology|December 21, 2018
Editorial: The potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignanciesGottfried E Konecny, Peter A Fasching
Breast Care (Basel, Switzerland)|December 7, 2016
Neoadjuvant Treatment of Breast Cancer - Advances and LimitationsPeter A Fasching, Paul Gaß, Alexander Hein
Breast Care (Basel, Switzerland)|April 2, 2020
Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620Michael Untch, Sibylle Loibl, Peter A Fasching
Archives of Gynecology and Obstetrics|July 17, 2014
Response to "screening depression during and after pregnancy using the EPDS"Alexander Hein, Peter A Fasching, Tamme W Goecke
Pageof 81

Showing results (1-10 of 810) with videos related to

Sort By:
Pageof 81
The Lancet. Oncology|January 17, 2018
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?Peter A Fasching
Clinical Advances in Hematology & Oncology : H&O|May 13, 2024
PROTAC drugs in cancer carePeter A Fasching
Cancers|November 27, 2021
Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of ImprovementNaiba Nabieva, Peter A Fasching
Cancers|March 29, 2023
CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast CancerNaiba Nabieva, Peter A Fasching
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Breast Cancer and Genetic <i>BRCA1/2</i> Testing in Routine Clinical Practice: Why, When and For Whom?Michael P Lux, Peter A Fasching
The Lancet. Oncology|January 2, 2007
Hormones and genetics caught in the crossfire of preventive medicinePeter A Fasching, Matthias W Beckmann
Current Opinion in Obstetrics & Gynecology|December 21, 2018
Editorial: The potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignanciesGottfried E Konecny, Peter A Fasching
Breast Care (Basel, Switzerland)|December 7, 2016
Neoadjuvant Treatment of Breast Cancer - Advances and LimitationsPeter A Fasching, Paul Gaß, Alexander Hein
Breast Care (Basel, Switzerland)|April 2, 2020
Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620Michael Untch, Sibylle Loibl, Peter A Fasching
Archives of Gynecology and Obstetrics|July 17, 2014
Response to "screening depression during and after pregnancy using the EPDS"Alexander Hein, Peter A Fasching, Tamme W Goecke
Pageof 81